Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 8/20 | 0.59 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.41 |
| ▸ | PDE4A | P27815 | 8/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.39 |
| ▸ | BRD4 | O60885 | 4/20 | 0.35 |
| ▸ | EP300 | Q09472 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | FABP4 | P15090 | 2/20 | 0.32 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8268935 | 0.88 | PDE4D (0.76) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL13631996 | 0.84 | PDE4D (0.57) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL13631919 | 0.77 | PDE4D (0.67) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL4029909 | 0.76 | PDE4D (0.81) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL13632195 | 0.75 | PDE4D (0.68) | PDE4DPDE4BPDE4APDE4C | |
| Oglemilast SCHEMBL220245 | 0.74 | PDE4D (1.00) | PDE4DPDE4BPDE4APDE4C | |
| Oglemilast SCHEMBL29413215 | 0.74 | PDE4D (1.00) | PDE4DPDE4BPDE4APDE4C | |
| Oglemilast SCHEMBL29369504 | 0.74 | PDE4D (1.00) | PDE4DPDE4BPDE4APDE4C | |
| Oglemilast SCHEMBL4030005 | 0.74 | PDE4D (0.98) | PDE4DPDE4BPDE4APDE4C | |
| Oglemilast SCHEMBL4030019 | 0.74 | PDE4D (0.98) | PDE4DPDE4BPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281146-A1 | PROCESS FOR THE PREPARATION OF N-(3,5-DICHLOROPYRID-4-YL)-4-DIFLUOROMETHOXY-8-METHANESULFONAMIDO-DIBENZO[B,D]FURAN-1-CARBOXAMIDE | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281146-A1 | PROCESS FOR THE PREPARATION OF N-(3,5-DICHLOROPYRID-4-YL)-4-DIFLUOROMETHOXY-8-METHANESULFONAMIDO-DIBENZO[B,D]FURAN-1-CARBOXAMIDE | DHODH, QDPR, DPYD | PDE4D 278/4885PDE4B 587/4885PDE4A 1099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.